Search Results - "CRESPEIGNE, N"

Platelet function testing in apheresis products: flow cytometric, resonance thrombographic (RTG) and rotational thrombelastographic (roTEG) analyses by Gutensohn, K., Geidel, K., Kroeger, N., Eifrig, B., Crespeigne, N., Kuehnl, P.

“…During storage of platelet concentrates, quality control of the units is mandatory. This includes the important testing of the hemostatic function of…”
Get full text

Biocompatibility of a new cell separator studied by flow cytometry: analyses of platelet antigens during apheresis and storage by Gutensohn, K., Alisch, A., Crespeigne, N., Eifrig, B., Kuehnl, P.

“…BACKGROUND: Alterations of platelet antigens are known to occur during cytapheresis and storage. These changes have been shown to be dependent on the…”
Get full text

Annexin V and platelet antigen expression is not altered during storage of platelet concentrates obtained with the AMICUS™ cell separator by Gutensohn, K, Alisch, A, Geidel, K, Crespeigne, N, Kuehnl, P

“…During storage of platelet concentrate the so-called “storage lesion” occurs. During this time, platelets loose their morphological and functional capacities…”
Get full text

Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial by Bleiberg, H, Gerard, B, Dalesio, O, Crespeigne, N, Rozencweig, M

“…Alizapride is a methoxy-2-benzamide derivative three times more potent than its parent compound, metoclopramide, as an antagonist of apomorphine-induced emesis…”
Get full text

Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex by Dodion, P F, de Valeriola, D, Crespeigne, N, Kantrowitz, J D, Piccart, M, Wery, F, Kerger, J, Egorin, M J, Forrest, A, Bachur, N R

“…Forty-six patients with refractory solid malignancies received the new platinum complex [2,2-bis(aminomethyl)-1,3-propanediol-N-N']…”
Get more information

Phase I study of carboplatin given on a five-day intravenous schedule by Rozencweig, M, Nicaise, C, Beer, M, Crespeigne, N, Van Rijmenant, M, Lenaz, L, Kenis, Y

“…Twenty-six adult patients were entered in a phase I trial of carboplatin, a new cisplatin derivative with reduced potential for nephrotoxicity. All patients…”
Get more information

Phase I study of intravenous menogaril administered intermittently by Dodion, P, Sessa, C, Joss, R, Crespeigne, N, Willems, Y, Kitt, M, Abrams, J, Finet, C, Brewer, J E, Adams, W J

“…Thirty-three adult patients with solid tumors were treated with menogaril, a new anthracycline antibiotic. The drug was given as a two-hour infusion every 4 to…”
Get more information

Intraperitoneal chemotherapy with cisplatin and melphalan by Piccart, M J, Abrams, J, Dodion, P F, Crespeigne, N, Sculier, J P, Pector, J C, Finet, C, Nouwijnck, C, Bondue, H, Atassi, G

“…Cisplatin and melphalan given ip exert a synergistic therapeutic effect against ascitic P388 leukemia in mice and have different dose-limiting toxic effects as…”
Get more information

Phase I study of oral idarubicin given with a weekly schedule by Dodion, P, Finet, C, Crespeigne, N, Beer, M, Nicaise, C, Rozencweig, M, Kenis, Y

“…Thirty one patients with solid tumors were entered into a phase I trial with idarubicin, a new anthracycline antibiotic with oral antitumor activity in…”
Get full text

Phase I clinical trial of oral menogaril administered on three consecutive days by Dodion, P, de Valeriola, D, Crespeigne, N, Peeters, B, Wery, F, van Berchem, C, Joggi, J, Kenis, Y

“…Eighteen adult patients with solid tumors were treated with oral menogaril, a new anthracycline antibiotic active against human breast cancer after intravenous…”
Get more information

Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin) by Dodion, P, Davis, T A, Rozencweig, M, Crespeigne, N, Kenis, Y, Bachur, N R

“…The pharmacokinetics of esorubicin, a new anthracycline antibiotic, was investigated in conjunction with a phase I clinical trial. The drug was administered to…”
Get full text

Phase I study of triglycidylurazol given on a 5-day i.v. schedule by Nicaise, C, Rozencweig, M, Crespeigne, N, Dodion, P, Gerard, B, Lambert, M, Decoster, G, Kenis, Y

“…Triglycidylurazol is a teroxirone derivative proposed for clinical trials on the basis of a broad spectrum of activity against murine tumors and a reduced…”
Get more information

Phase I clinical study of 9-hydroxy-2N-methyl-ellipticinium acetate (NSC-264137) administered on a 5-day i.v. schedule by Dodion, P, Rozencweig, M, Nicaise, C, Piccart, M, Cumps, E, Crespeigne, N, Kisner, D, Kenis, Y

“…Twenty-three patients with advanced solid tumors received 9-hydroxy-2N-methyl-ellipticinium acetate at a single daily i.v. dose of 15-80 mg/m2 for 5…”
Get more information

Phase I clinical trial with carbetimer by Dodion, P, de Valeriola, D, Body, J J, Houa, M, Noel, P, Abrams, J, Crespeigne, N, Wery, F, Kenis, Y

“…Carbetimer, a low molecular weight polymer derived from ethylene and maleic anhydride, belongs to a class of chemical compounds different from previously…”
Get more information

Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days by Dodion, P, de Valeriola, D, Crespeigne, N, Peeters, B, Wery, F, van Berchem, C, Piccart, M, Tueni, E, Joggi, J, Kenis, Y

“…Eighteen adult patients with solid tumors were treated with oral menogaril, a new anthracycline antibiotic active against human breast cancer after intravenous…”
Get more information

Phase II trial with chlorozotocin in advanced colorectal cancer by Bleiberg, H, Rozencweig, M, Michel, J, Clavel, M, Longeval, E, Feremans, W, Bondue, H, Lardinois, J, Crespeigne, N, Kenis, Y

Get more information

Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study by Schwartsmann, G, van der Vijgh, W J, van Hennik, M B, Klein, I, Vermorken, J B, Dodion, P, ten Bokkel Huinink, W W, Joggi, G, Gall, H, Crespeigne, N

“…The pharmacokinetics of the novel antipyrimidine agent Brequinar sodium (NSC 368390; DUP 785) was studied in 23 patients with solid tumors during the phase I…”
Get more information

Activity of a new antiemetic agent: alizapride by BLEIBERG, H, GERARD, B, DALESIO, O, CRESPEIGNE, N, ROZENCWEIG, M

Get full text

Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies by SCHWARTSMANN, G, DODION, P, CRESPEIGNE, N, PINEDO, H. M, VERMORKEN, J. B, TEN BOKKEL HUININK, W. W, JOGGI, J, WINOGRAD, B, GALL, H, SIMONETTI, G, VAN DER VIJGH, W. J. F, VAN HENNIK, M. B

“…Brequinar sodium (DUP 785, NSC 368390) is a novel quinoline-carboxylic acid derivative that has been selected for clinical evaluation because of its broad…”
Get full text

O16-4 Antigènes plaquettaires et interactions plaquettes-leucocytes chez les donneurs pendant l'aphérèse et dans les concentrés de plaquettes pendant le stockage by Gutensohn, K, Alish, A, Preuss, J, Loeliger, C, Geidel, K, Crespeigne, N, Krueger, W, Kuehnl, P

Get full text